At a glance
ClinicalIndex Comparison RecordN/ACompleted· 86 enrolled
Drug / intervention
Refacto FusENGOdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non Interventional Longitudinal Study To Assess The Acceptability And The Satisfaction Of Patients With Haemophilia A Treated Both On Demand And On Prophylaxis With A New Factor Viii Delivery System Fusengo
In Brief
An observational study evaluating Refacto FusENGO for Hemophilia A. Completed, enrolled 86 participants across 19 sites.
Detailed Summary
This study aims to investigate prospectively throughout a period of 3- 6 months and not to exceed 12 months (according to local therapeutic plans) patients experiences of treatment with Factor VIII in the new device named FuseNGO, a new delivery system for Factor VIII compared to their previous delivery system.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHemophilia A
CountriesItaly
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 2013
Enrollment StartJan 2014
Primary CompletionDec 2016
TodayJul 2026
First PostedOct 10, 2013
Enrollment StartJan 27, 2014
Primary CompletionDec 12, 2016
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 12.7 years ago
Interventions
Refacto FusENGOdevice
Dosage will be chosen by PI based on patient condition.